Thrombotic microangiopathy: New insights

Current Opinion in Nephrology and Hypertension

Volumn 19, Issue 3, 2010, Pages 242-247

  Benz, Kerstin ^a   Amann, Kerstin ^b  

^a Department of Pediatrics ^*  (United States)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Haemolytic uremic syndrome; Pathogenesis; Pathology; Thrombocytic thrombocytopenic purpura; Thrombotic microangiopathy

Indexed keywords

BELATACEPT; BEVACIZUMAB; BORTEZOMIB; CALCINEURIN INHIBITOR; CLOPIDOGREL; DACLIZUMAB; DEFIBROTIDE; ECULIZUMAB; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB; SORAFENIB; SUNITINIB; TICLOPIDINE; VASCULOTROPIN INHIBITOR; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

AUTOIMMUNE DISEASE; CLINICAL TRIAL; COMPLEMENT SYSTEM; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; GLOMERULONEPHRITIS; GRAFT REJECTION; HEMATURIA; HEMOLYTIC UREMIC SYNDROME; HEREDITY; HUMAN; HYPERTENSION; INTERSTITIAL NEPHRITIS; MALIGNANT HYPERTENSION; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; REVIEW; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

HEMOLYTIC-UREMIC SYNDROME; HUMANS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; THROMBOTIC MICROANGIOPATHIES;

EID: 77951468298     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3283378f25     Document Type: Review

References (34)

1. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, haemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001; 60:831-846.
2. Tsai HM. The kidney in thrombotic thrombocytopenic purpura. Minerva Med 2007; 98:731-747.
3. Fakhouri F, Fremeaux-Bacchi V. Does haemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura? Nat Clin Pract Nephrol 2007; 3:679-687.
4. Desch K, Motto D. Is there a shared pathophysiology for thrombotic thrombocytopenic purpura and haemolytic-uremic syndrome? J Am Soc Nephrol 2007; 18:2457-2460.
5. Benz K, Amann K. Pathological aspects of membranoproliferative glomerulonephritis (MPGN) and haemolytic uraemic syndrome (HUS)/thrombocytic thrombopenic purpura (TTP). Thromb Haemost 2009; 101:265-270.
6. Zipfel PF. Thrombotic microangiopathies as a prime example for translational medicine. Thromb Haemost 2009; 101:225-226.
7. Martinez-Barricarte R, Pianetti G, Gautard R, et al., European Working Party on the Genetics of HUS. The complement factor H R1210C mutation is associated with atypical haemolytic uremic syndrome. J Am Soc Nephrol 2008; 19:639-646.
8. Pickering MC, Cook HT. Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol 2008; 151:210-230.
9. Scheiring J, Rosales A, Zimmerhackl LB. Clinical practice. Today's understanding of the haemolytic uraemic syndrome. Eur J Pediatr 201 0; 169:7-13.
10. Skerka C, Licht C, Mengel M, et al. Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: indications for a disease spectrum and common pathogenic principles. Mol Immunol 2009; 46:2801-2807.
11. Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009; 9:729-740.
12. Skerka C, Jozsi M, Zipfel PF, et al. Autoantibodies in haemolytic uraemic syndrome (HUS). Thromb Haemost 2009; 101:227-232.
13. Strobel S, Hoyer PF, Mache CJ, et al. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrol Dial Transplant 2010; 25:136-144.
14. Licht C, Pluthero FG, Li L, et al. Platelet-associated complement factor H in normal individuals and patients with atypical HUS. Blood 2009; 114:4538-4545.
15. Orth D, Khan AB, Naim A, et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 2009; 182:6394-6400.
16. Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin mutations in atypical haemolytic-uremic syndrome. N Engl J Med 2009; 361:345-357.
17. Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical haemolytic uremic syndrome in children. Pediatr Nephrol 2008; 23:1957-1972.
18. Saland JM, Ruggenenti P, Remuzzi G, Consensus Study Group. Liver-kidney transplantation to cure atypical haemolytic uremic syndrome. J Am Soc Nephrol 2009; 20:940-949.
19. Loirat C, Fremeaux-Bacchi V. Haemolytic uremic syndrome recurrence after renal transplantation. Pediatr Transplant 2008; 12:619-629.
20. LeQuintrec M, Lionet A, Kamar N, et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 2008; 8:1694-1701.
21. Dubois EA, Cohen AF. Eculizumab. Br J Clin Pharmacol 2009; 68:318-319.
22. Mache CJ, Acham-Roschitz B, Fremeaux-Bacchi V, et al. Complement inhibitor eculizumab in atypical haemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4:1312-1316.
23. Nurnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical haemolyticuremic syndrome. N Engl J Med 2009; 360:542-545
24. Coppo P, Veyradier A. Thrombotic microangiopathies: towards a pathophy-siology-based classification. Cardiovasc Hematol Disord Drug Targets 2009; 9:36-50.
25. De Serres SA, Isenring P. Athrombocytopenic thrombotic microangiopathy, a condition that could be overlooked based on current diagnostic criteria. Nephrol Dial Transplant 2009; 24:1048-1050.
26. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358:1129-1136.
27. Bollee G, Patey N, Cazajous G, et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 2009; 24:682-685.
28. Gurevich F, Perazella MA. Renal effects of antiangiogenesis therapy: update for the internist. Am J Med 2009; 122:322-328.
29. Zakarija A, Kwaan HC, Moake JL, et al. Ticlopidine-and clopidogrel-asso-ciated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl 2009; 112:S20-S24.
30. Fine DM, Fogo AB, Alpers CE. Thrombotic microangiopathy and other glomerular disorders in the HIV-infected patient. Semin Nephrol 2008; 28:545-555.
31. Matsuyama T, Kuwana M, Matsumoto M, et al. Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases. Thromb Haemost 2009; 102:371-378.
32. Choi CM, Schmaier AH, Snell MR, Lazarus HM. Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment. Drugs 2009; 69:183-198.
33. Stegall MD, Gloor JM. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment. Curr Opin Organ Transplant 2010; 15:8-10.
34. Ashman N, Chapagain A, Dobbie H, et al. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. Am J Transplant 2009; 9:424-427.